77 Ces Urol 2023; 27(2): 70-77 PŘEHLEDOVÉ ČLÁNKY 26. El‑Zaatari Z, Divatia MK. Hereditary leiomyomatosis and renal cell carcinoma syndrome‑associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses. Indian J Pathol Microbiol. 2020; 63(Supplement): S7–17. 27. Kuroda N, Tsutsui M, Iguchi M, et al. Fumarate hydratase‑deficient renal cell carcinoma: A clinicopatho‑ logical study of seven cases including hereditary and sporadic forms. Ann Diagn Pathol. 2020; 49: 151599. 28. Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015; 28(6): 845–853. 29. Wang Y, Zhao P, Wang L, et al. Analysis of clinicopathological and molecular features of ELOC(TCEB1)‑ -mutant renal cell carcinoma. Pathol Res Pract. 2022; 235: 153960. 30. Shah RB, Stohr BA, Tu ZJ, et al. „Renal Cell Carcinoma With Leiomyomatous Stroma“ Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. Am J Surg Pathol. 2020; 44(5): 571–581. 31. Iannantuono GM, Riondino S, Sganga S, Roselli M, Torino F. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. Int J Mol Sci. 2022; 23(7): 3995. 32. Pal SK, Bergerot P, Dizman N, et al. Responses to Alectinib in ALK‑rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018; 74(1): 124–128. 33. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012; 61(3): 428–435.
RkJQdWJsaXNoZXIy NDA4Mjc=